tiprankstipranks
Evaxion Biotech Advances AI-Driven Vaccine Development
Company Announcements

Evaxion Biotech Advances AI-Driven Vaccine Development

Evaxion Biotech A/S Adr (EVAX) has released an update.

Pick the best stocks and maximize your portfolio:

Evaxion Biotech A/S has launched a precision vaccine initiative using AI to identify new cancer targets and aims for preclinical proof-of-concept by H2 2024. The company completed key phases of a vaccine collaboration with MSD and secured significant funding through a private placement and a public offering, with MSD GHI becoming the largest shareholder. Evaxion’s R&D Day highlighted the potential of their AI-Immunology platform in vaccine discovery and the company’s strategy for value generation.

For further insights into EVAX stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskEvaxion Biotech Advances AI-Driven Precision Cancer Vaccine Concept
TheFlyEvaxion Biotech establishes new Ai-derived precision cancer vaccine concept
TheFlyEvaxion Biotech announces strategic milestones for 2025
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App